SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005; 46: 35-48.
  • 2
    Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol. 2005; 114: 41-51.
  • 3
    Horny H, Metcalfe, DD, Bennett, JM, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008: 54-63.
  • 4
    Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009; 113: 5727-5736.
  • 5
    Pardanani A, Lim KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010; 115: 150-151.
  • 6
    Zanotti R, Bonadonna P, Bonifacio M, et al. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica. 2011; 96: 482-484.
  • 7
    Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010; 125: 1269-1278.
  • 8
    Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol. 2010; 125: 719-726.
  • 9
    Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009; 124: 514-521.
  • 10
    Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25: 603-625.
  • 11
    Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006; 8: 412-419.
  • 12
    Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009; 114: 3769-3772.
  • 13
    Stevens EC, Rosenthal NS. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol. 2001; 116: 177-182.
  • 14
    Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res. 2004; 28: 777-783.
  • 15
    Valent P, Akin C, Metcalfe DD. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest. 2007; 37: 153-154.
  • 16
    Johnson MR, Verstovsek S, Jorgensen JL, et al. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009; 22: 50-57.
  • 17
    Homann J, Kolck U, Molderings GJ. Mastocytosis. A disease of the hematopoietic stem cell. Dtsch Arztebl Int. 2009; 106: 173-174.
  • 18
    Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood. 2007; 110: 2331-2333.
  • 19
    Sotlar K, Colak S, Bache A, et al. Variable presence of KITD816V in clonal haematological non-mast lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010; 220: 586-595.
  • 20
    Valent P, Cerny-Reiterer S, Herrmann H, et al. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol. 2010; 23: 369-378.
  • 21
    Tefferi A, Verstovsek S, Pardanani A. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica. 2008; 93: 6-9.
  • 22
    Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood. 1978; 52: 447-452.
  • 23
    Kitamura Y, Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood. 1979; 53: 492-497.
  • 24
    Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995; 92: 10560-10564.
  • 25
    Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996; 12: 312-314.
  • 26
    Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset [serial online]. PLoS One. 2008; 3: e1906.
  • 27
    Mol CD, Lim KB, Sridhar V, et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem. 2003; 278: 31461-31464.
  • 28
    Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993; 92: 1736-1744.
  • 29
    Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol. 2004; 114: 13-19; quiz 20.
  • 30
    Gleixner K, Mayerhofer M, Rix U, et al. Delineation of the KIT-independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk and can be disrupted with the KIT/Lyn/Btk-targeting drug dasatinib. Blood. 2007; 110: 460a-461a.
  • 31
    Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360: 2289-2301.
  • 32
    Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009; 23: 900-904.
  • 33
    Traina F, Jankowska A, Makishima H, et al. New TET2, ASXL1, and CBL mutations have poor prognostic impact in systemic mastocytosis and related disorders [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 3076.
  • 34
    Wilson T, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011; 96: 459-463.
  • 35
    Niedoszytko M, Oude Elberink JN, Bruinenberg M, et al. Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis. Allergy. 2011; 66: 229-237.
  • 36
    Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am. 2000; 14: 659-687, vii.
  • 37
    Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007; 119: 1550-1551.
  • 38
    Siebenhaar F, Kuhn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol. 2007; 120: 213-215.
  • 39
    Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 1998; 138: 489-495.
  • 40
    Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002; 119: 1090-1097.
  • 41
    Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of 5 cases and review of the literature. Leuk Res. 2004; 28: 249-257.
  • 42
    Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009; 84: 790-794.
  • 43
    Hermine O, Hirsh I, Damaj G, et al. Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 1982.
  • 44
    Lortholary O, Vargaftig J, Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 33 patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2004; 104. Abstract 661.
  • 45
    Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003; 102: 4270-4276.
  • 46
    Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108: 2366-2372.
  • 47
    Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006; 107: 1429-1439.
  • 48
    Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000; 96: 925-932.
  • 49
    Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003; 31: 686-692.
  • 50
    Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009; 33: 1481-1484.
  • 51
    Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006; 107: 345-351.
  • 52
    Nakagomi N, Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest. 2007; 87: 365-371.
  • 53
    Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004; 104: 3038-3045.
  • 54
    Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008; 14: 2717-2725.
  • 55
    Gleixner K, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006; 107: 752-759.
  • 56
    Schatz M, Verhoef G, Gattermann N, et al. A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM) [abstract]. J Clin Oncol. 2006; 24( 18S). Abstract 6588.
  • 57
    Lombardo L, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-[4-(2-hydroxyethyl)-piperazin-1-yl]-2-methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47: 6658-6661.
  • 58
    Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006; 108: 286-291.
  • 59
    Schittenhelm M, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006; 66: 473-481.
  • 60
    Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008; 14: 3906-3915.
  • 61
    Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest. 2008; 38: 869-873.
  • 62
    Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: 4 cases. Eur J Haematol. 2008; 80: 456-458.
  • 63
    Fabbro D, Ruetz S, Bodis S, et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000; 15: 17-28.
  • 64
    Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of 2 tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007; 92: 1451-1459.
  • 65
    Gotlib J, DeAngelo DJ, George TI, et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 316.
  • 66
    Pardanani A, Tefferi A. A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol. 2010; 84: 371-378.
  • 67
    Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT [serial online]. PLoS One. 2009; 4: e7258.
  • 68
    Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008; 22: 1301-1309.
  • 69
    Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010; 85: 921-925.
  • 70
    Garton AJ, Crew AP, Franklin M, et al. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res. 2006; 66: 1015-1024.
  • 71
    Kelly L, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002; 1: 421-432.
  • 72
    Dorsey J, Jove R, Kraker AJ, et al. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210 Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000; 60: 3127-3131.
  • 73
    Wisniewski D, Lambek CL, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 2002; 62: 4244-4255.
  • 74
    Corbin A, Demehri S, Griswold IJ, et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood. 2005; 106: 227-234.
  • 75
    Liao A, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood. 2002; 100: 585-593.
  • 76
    Gazit A, Yee K, Uecker A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem. 2003; 11: 2007-2018.
  • 77
    Pan J, Quintas-Cardama A, Kantarjian HM, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007; 109: 315-322.
  • 78
    Corbin A, Griswold IJ, La Rosee P, et al. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood. 2004; 104: 3754-3757.
  • 79
    Damaj G, Bernit E, Ghez D, et al. Thalidomide in advanced mastocytosis. Br J Haematol. 2008; 141: 249-253.
  • 80
    Kluin-Nelemans HC, Ferenc V, van Doormaal JJ, et al. Lenalidomide therapy in systemic mastocytosis. Leuk Res. 2009; 33: e19-e22.
  • 81
    Escribano L, Diaz-Agustin B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001; 25: 563-570.
  • 82
    Quintas-Cardama A, Kantarjian H, Verstovsek S. Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol. 2007; 82: 1124.
  • 83
    Quintas-Cardama A, Amin HM, Kantarjian H, Verstovsek S. Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma. 2010; 51: 540-542.
  • 84
    Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010; 51: 269-274.
  • 85
    Weiler SR, Mou S, DeBerry CS, et al. JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood. 1996; 87: 3688-3693.
  • 86
    Lasho T, Tefferi A, Pardanani A. Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia. 2010; 24: 1378-1380.
  • 87
    Aichberger KJ, Gleixner KV, Mirkina I, et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood. 2009; 114: 5342-5351.
  • 88
    Moller C, Alfredsson J, Engstrom M, et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood. 2005; 106: 1330-1336.
  • 89
    Ruano I, Izquierdo M. Selective RNAi-mediated inhibition of mutated c-kit. J RNAi Gene Silencing. 2009; 5: 339-344.
  • 90
    Ruano I, Gargini R, Izquierdo M. Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis. Br J Haematol. 2010; 148: 59-68.
  • 91
    Jin Y, Chen Q, Shi X, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 2009; 100: 1335-1343.
  • 92
    Jin Y, Lu Z, Cao K, et al. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther. 2010; 9: 21-23.
  • 93
    Lin TY, Bear M, Du Z, et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol. 2008; 36: 1266-1277.